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Background: Bioactive compounds from plants (i.e., Serenoa repens) are often used in medicine in the treatment of
several pathologies, among which benign prostatic hyperplasia (BPH) associated to lower urinary tract symptoms
(LUTS).
Discussion: There are different techniques of extraction, also used in combination, with the aim of enhancing the
amount of the target molecules, gaining time and reducing waste of solvents. However, the qualitative and
quantitative composition of the bioactives depends on the extractive process, and so the brands of the recovered
products from the same plant are different in terms of clinical efficacy (no product interchangeability among
different commercial brands).
Summary: In this review, we report on several and recent extraction techniques and their impact on the
composition/biological activity of S. repens-based available products.
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Benign prostatic hyperplasia (BPH) is a significant health
concern and increases in prevalence as the population
ages. Symptomatic BPH represents the most common
urologic disease among elderly males, affecting about one-
quarter of men in their ‘50s, one-third of men in their
‘60s, and about half of octogenarians. BPH is considered a
chronic disease with early initiation and slow progression.
BPH starts as a simple micro nodular hyperplasia and
evolves into a macroscopic nodular enlargement that may
result in bladder prostatic obstruction (BPO), causing
lower urinary tract symptoms (LUTS) [1,2]. When consid-
ering options for managing LUTS, which may suggest
BPO, the short term goal is to improve the individual’s* Correspondence: gb.dipierro@libero.it
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article, unless otherwise stated.quality of life by relieving symptoms, however, the aim
should be to prevent or reduce the worsening of symp-
toms over longer term and limiting BPH progression
[3]. Medical treatment options of LUTS/BPO include
α1-adrenoceptor antagonists, 5α-reductase inhibitors,
anti-cholinergic agents, phosphodiesterase 5 inhibitors
and plant extracts. Although the European Association
of Urology is unable to make specific recommendations
about plant extracts treatment in patients with LUTS/
BPH because of the heterogeneity of the marketed prod-
ucts and the methodological problems associated with
meta-analysis, their use in clinical practice is rising with
an increased global prescription index, particularly in
some European countries (Belgium, Hungary, Poland,
France) [2,4,5]. Furthermore, the treatment of BPH with
α-blockers and 5α-reductase inhibitors could play an
important role in the alteration of sexual functions lead-
ing to ejaculatory and erectile disorders [6]. To avoidtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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been using for treating BPH, especially extracts of Serenoa
repens (saw palmetto) obtained from the American dwarf
palm [7-9].
Nowadays, a lot of extractive strategies with differences
in terms of methodology, time, temperature, pressure and
solvents have been developed, also used in combination
with other techniques in order to improve the recovery
and, consequently, the pharmacological profile of their
extracts. However, as a consequence of the differences
among the extractive processes used by several companies,
there is a discrepancy in the qualitative and quantitative
composition of the extracts obtained from the same plant.
Hence, each brand is different in quality and efficacy for
the content of the bioactive compounds with repercus-
sions on the beneficial effects for patients in response to
clinical trials and treatments [10].
Discussion
The aim of this review is the evaluation of the available
evidence on plant extraction and its possible clinical impli-
cations on S. repens therapeutic efficacy.
Serenoa repens as a standard reference material (SRM)
The knowledge of the exhaustive quali-quantitative com-
position of S. repens extracts is warranted not only due to
the multiple variables associated to different extraction
techniques, but also due to the not yet fully understood
pharmacological profile of each active principle.
For this reason, the validation of appropriate analyt-
ical methods, to develop standard reference materials
for selected dietary supplements, have been regulated
by the National Institute of Health’s Office of Dietary
Supplements and the Food and Drug Administration’s
Center for Drug Evaluation and Research in collaboration
with the National Institute of Standards and Technology
(NIST) [11].
NIST, as a non-regulatory federal agency of USA, sup-
ports accurate and compatible measurements by certifying
and providing over 1300 Standard Reference Materials®
(SRMs) with well-characterized composition or properties.
Each NIST Standard Reference Material® is supplied with
a Certificate of Analysis and/or a Materials Safety Data
Sheet. In addition, NIST has published many articles and
practice guides that describe the development, analysis,
traceability and use of SRMs. Certified concentration
values are usually determined by two or more independent
methods, which could be combined with data from other
laboratories.
In the case of saw palmetto, two reference materials
have been reported, SRM 3250 S. repens ground fruit
and SRM 3251 S. repens extract. SRM 3250 has certified
concentration values for specific phytosterols, and fatty
acids (free or as triglycerides). On the other hand, theextract SRM 3251 has certified concentration values
for phytosterols, fatty acids (free or as triglycerides),
β-carotene and its isomers, and γ- and δ-tocopherol.
For SRM 3250 three extraction procedures and condi-
tions for each procedure were evaluated including PFE
(pressurized fluid extraction), Soxhlet extraction (with
dichloromethane), and sonication. PFE and Soxhlet extrac-
tion gave the highest amounts of extracted fatty acids from
the ground fruit. In the case of PFE (conditions: solvent
mixture of 4:1 (v/v) of hexane/acetone with a four static
cycle extraction at 125°C and 10.4 MPa), the choice of
solvent, temperature of extraction, and pressure of ex-
traction did not have significant effects on the compos-
ition of the extracted fractions. The solvent choice also
did not have a deep impact on the efficiency of the
Soxhlet extraction, although the duration of the extrac-
tion time was critical (at least 40 h). Conversely, SRM
3251 has been obtained as a supercritical CO2 extract
and analyzed with respect to the corresponding extracts
obtained for SRM 3250.
As reported in Table 1, the concentrations of the fatty
acids as triglycerides were 6–25 times higher in SRM
3251 compared with SRM 3250. In general, the concen-
tration of each fatty acid as a triglyceride was higher
than the corresponding free fatty acid for both extracts.
The concentration of linoleic and α-linoleic acid in SRM
3250 was approximately six times lower than in SRM
3251. Linoleic and α-linolenic acids were also lower in
concentration as free fatty acids in both SRM 3250 and
SRM 3251 as compared with the corresponding fatty
acids as triglycerides.
These SRMs could also furnish appropriate reference
materials to make comparisons among dietary supple-
ments. In fact, SRM 3251 has the second highest con-
centration of linoleic acid, as regards the triglycerides,
compared with the other available SRMs (i.e., fish oil
and tissues), and the highest concentration of α-linolenic
acid. As regards the phytosterols content, in both SRMs,
campesterol, β-sitosterol and stigmasterol have certified
concentration values (higher in SRM 3251 than SRM
3250). Furthermore, β-carotene (46.8 μg/g), γ-tocopherol
(280 μg/g) and δ-tocopherol (35.3 μg/g) were also
quantified.
Extraction techniques
Many plants possess bioactive metabolites that can be
used as therapeutic agents for the treatment of human
pathologies like BHP associated to LUTS. Because of the
very low concentrations of therapeutic compounds in
plants, their exhaustive recovery becomes a crucial issue
in order to obtain high yields of the products with the
use of an extractive method that should be reproducible,
time saving and eco-friendly. Furthermore, in the choice
of the extractive method, it is important to keep in mind
Table 1 Composition of Serenoa repens extracts as standard reference materials
Extract Fatty acids content (as triglycerides) Free fatty acids content on a dry mass basis
SRM 3250 (ground fruit)
2.96% (dodecanoic acid)
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http://www.biomedcentral.com/1471-2490/14/63the thermolability of the active molecules, hence the
temperature and the other parameters should be opti-
mized. For having an efficient process, three important
factors must be mainly considered: the sample matrix,
the type and the localization of bioactive compounds
within the matrix. In fact, the target compound firstlymust be removed from the site in which it is placed and
then it must diffuse towards the extraction phase to be
finally collected.
We briefly report on classical and innovative extraction
techniques which have been or could be applied to obtain
S. repens extracts enriched by specific active principles.
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According to the solubility of the bioactive compounds
there are a large number of inorganic, organic, polar and
non-polar solvents to perform a good extraction, also in
combination among them. If the substance of our interest
is lipophilic, the organic solvents of choice will be non-
polar, ranging from those with a very low polarity such as
hexane, to those that are less non-polar like chloroform
and dichloromethane. For example, the apolar solvents
cyclohexane, hexane, toluene, benzene, ether, chloroform
and ethyl acetate are currently used to extract alkaloids,
coumarins, fatty acids (FAs), flavonoids and terpenoids.
On the contrary, for hydrophilic compounds the choice
will fall on a polar solvent which may be non-protic such
as acetone, or protic such as ethanol, methanol or even
water. In fact acetone, acetonitrile, butanol, propanol and
ethanol are the solvents for the extraction of flavonols, lec-
tins, alkaloids, quassinoids, flavones, polyphenols, tannins
and saponins. One of the major pros of this procedure is
the use of simple equipment and its limited cost.
Microwave-assisted extraction
Microwave-assisted extraction (MAE) is an extractive
method based on the utilization of microwave energy
that is produced when the perpendicular oscillation be-
tween the electric and the magnetic fields generates elec-
tromagnetic radiations with a frequency ranging from 0.3
to 300 GHz. If the microwave goes through and interacts
with a substance there is a production of heat whose in-
tensity depends on the absorption of the energy by the
material and the dissipation of the resulting heat [12].
MAE techniques can be classified according to the
pressure through which they operate: higher than the at-
mospheric pressure (closed MAE system) and lower
than the atmospheric pressure (open MAE system). As
regards closed systems, the temperature is set over the
boiling point of the solvent and the pressure is under con-
trol to avoid an excessive development. Among the closed
systems we can enumerate high pressure microwave-
assisted extraction (HPMAE) which uses high pressure
and temperature in order to enhance the capacity of the
solvent to incorporate the energy from radiation and to
avoid large amount of solvent for the extraction. In case
of thermolabile molecules, soft conditions are needed
and so the choice will fall on an open system or the vac-
uum microwave assisted extraction (VMAE) that allows
the reduction of the boiling point of the solvent. For
compounds that are susceptible of oxidation it has been
developed the nitrogen-protected microwave-assisted
extraction operating under pressurized inert gas. When
the bioactive compounds are susceptible of hydrolysis
such as the essential oils, solvent-free microwave-assisted
extraction (SFME) is used to avoid the loss/degradation of
these products. Moreover, MAE can be associated toultrasonic energy (ultrasonic/microwave-assisted extrac-
tion UMAE) to reduce extraction times and the amounts
of solvent leading to an improvement of the yield. Another
way to gain time is coupling the extraction step with the
analytical one in the dynamic microwave-assisted extrac-
tion (DMAE) which operates continuously and automatic-
ally. The choice of the solvent is influenced by its ability to
absorb the microwave radiation: ethanol, methanol, water
and the more selective room temperature ionic liquids are
good solvents for MAE. The ratio of solvent to solid is im-
portant for improving MAE: if the amount of solvent is
too much it absorbs all the energy with a resulting ineffi-
cient matrix heating, whereas if the ratio is too low the
amount of solvent is not enough to allow the diffusion of
the compounds out of the matrix. Also the vessel size is a
critical factor because in a little vessel the internal pressure
tends to augment and this could mean a degradation of
the more delicate molecules.
Another parameter to consider in MAE is the power
of extraction: an increased power boosts the temperature
reducing the solvent viscosity and leading to a better
efficiency, except in case of thermolabile molecules.
Microwave-assisted extraction gives several advantages
with respect to classical extractive processes such as
Soxhlet: MAE allows a gain of time, higher quality and
yields [13]. It is also cheaper than supercritical fluid
extraction (SFE) and faster than ultrasonic-assisted ex-
traction (UAE). On the other hand, MAE shows some
drawbacks: it is more expensive than UAE, less eco-
friendly than SFE due to the use of organic solvents,
not suitable for thermolabile compounds because the
irradiation could promote chemical reactions with the
loss of the desirable products, and not efficient when
the target molecules and/or the solvent of extraction
are non-polar because they do not absorb energy from
the source [14]. This technique has never been applied
to S. repens extraction.
Ultrasound-assisted extraction
In recent times, ultrasound-assisted extraction has re-
ceived a great interest to overcome the disadvantages
of classical solvent extractions such as little yields and
waste of time. UAE is based on the production of ultra-
sound waves and their transmission throughout the
solvent with a resulting cavitation. When the cavitation
bubbles collapse, there is a generation of liquid circulation
currents and turbulence that improve the mass transfer
rate. The fractures formed in the cell wall enhance its per-
meability and so a bigger amount of solvent can enter into
the plant tissues to extract the bioactive metabolites. In
order to perform an extraction based on sonochemistry,
the choice of solvent becomes an important parameter be-
cause its physical properties like polarity, viscosity, vapour
pressure and surface tension influence the cavitation
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in UAE, and sometimes water could be added to ethanol,
even if its amount must not be too much in order to avoid
a decrease in extraction efficiency, probably due to the
generation of radicals from the ultrasonic dissociation of
water [15]. Other parameters to be considered are the fre-
quency and the power: often the former ranges from 20 to
100 kHz and the latter from 100 to 800 W. Also the power
dissipation is a critical factor, because the generation of
physical effects like turbulence is directly proportioned to
the power dissipated as heat. For the future, the design of
reactors based on multiple transducers is needed in order
to operate at multiple frequencies and improve the efficacy
of UAE. Another problem that currently limits the use of
UAE at large scales is the erosion of transducers and their
continuous replacement to avoid a decrease in the trans-
mitted energy. Nonetheless, UAE is less expensive than
the traditional extractive techniques; it can give high quan-
tities of products without spending time and without
using large amounts of solvent. For a better performance,
UAE can be also used in combination with other tech-
niques like supercritical fluid process. This technique has
never been applied to S. repens extraction.
Supercritical fluid extraction
Supercritical fluid extraction is a novel technique espe-
cially used for the recovery of essential oil from plants.
SFE is based on the use of carbon dioxide in supercritical
phase, which is at low pressure and temperature (74 bar
and 32°C): in this state CO2 possesses a polarity similar to
pentane and so it is a good candidate for the extraction of
lipophilic compounds. Furthermore supercritical CO2 is
non toxic, non-flammable, not expensive, and easy to re-
move in the end of the process (eco-friendly). Operating
at low temperature it is possible to obtain in high yield
thermolabile compounds like terpenes and terpenoids that
normally have their boiling point over 150°C and so it is
important to work at lower temperatures for preventing
their degradation [16]. If the components to extract are
polar, a cosolvent like water or ethanol in little percentage
(5-10%) is needed to increase the extraction quality. When
in the plant matrix there are bioactive compounds of dif-
ferent solubility, a method to improve the recovery of all
the phytotherapeutics without any loss is the fractionation
of the extract [17]. Two strategies could be applied: the
multi-step fractionation and the on-line fractionation.
When the multi-step fractionation is performed, there
are different successive steps of separation with different
conditions in terms of density of CO2: in the first step
we will obtain the fraction of the more soluble compounds
such as essential oils, whereas in the second step, increas-
ing CO2 density we will have the recovery of the less sol-
uble components like antioxidants. Moreover, thanks to
this strategy we can obtain in the first step the productsextracted by the only use of supercritical CO2, while in a
second time we can add a cosolvent such as ethanol for
the other compounds. The on-line fractionation works,
instead, in a cascade depressurization system in order to
obtain the precipitation of the several fractions according
to their saturation conditions. The particular properties of
the supercritical fluid characterized by a low viscosity and
a high diffusion make this technique an excellent alterna-
tive to the others for the recovery of therapeutic products
from plants.
Ionic liquids
The use of ionic liquid (IL) for analytical purposes
has been developed in modern times with advantages
in terms of quality and efficacy of extraction. In particular,
an ionic liquid consists of a liquid organic salt that select-
ively interacts with specific polar and non-polar com-
pounds thanks to ion-exchanges, π-stacking interactions,
hydrophobic interactions or hydrogen bonds, improving
the selectivity of the extractive method [18]. For example,
the interaction of 1-butyl-3-methylimidazolium hexafluor-
ophosphate ([BMIM][PF6]) with hydrophilic amino acids
enhances the extraction efficiency with respect to a
traditional organic solvent extraction. Being ILs applied
in several extractive processes such as MAE and UAE,
they should be stable enough to resist to the high temper-
atures through which the technique works. About this







−, possess a great thermal
stability; moreover, the organic anions have shown to be
more stable than the inorganic ones when operating at
elevated temperatures. In conclusion, extraction based
on ILs represents a good choice to recover in high yields
organic and inorganic and metal ions as bioactive com-
ponents of plants and herbs. This technique has never
been applied to S. repens extraction.
Enzyme-assisted extraction
An alternative approach to classical solvent extraction
techniques is the enzyme-assisted extraction: this method
is innovative and convenient thanks to the fact that the
enzymes catalyze reactions in a specific way without oper-
ating under strong conditions that could lead to the deg-
radation of the desired products. In addition, proteins like
cellulases, hemicellulases and pectinases disrupt cell wall
with the hydrolysis of its components leading to a major
permeability and allowing an easier release of the metabo-
lites from plants [19]. The application of enzymes such as
lipases, proteases, phospholipases, permits to reduce the
use of the solvent for the extraction. For oil extraction
from plants, cellulase, α-amylase and pectinase are the
most used enzymes. These proteins can be obtained from
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gineering methods and, thanks to their selective catalysis,
they can be used to recover a specific bioactive compound
in high yields and in a “green” approach, without wasting
too much energy. Nevertheless, there are some limitations
due to the cost of the enzymatic approach, the incomplete
disruption of the cell wall and the complicated application
in a commercial scale because of the different behaviour
of the enzymes according to the environmental circum-
stances such as the amount of oxygen, the variety of nutri-
ents and the operating temperature. This technique has
never been applied to S. repens extraction.
Pressurized liquid/fluid extraction
Pressurized liquid extraction (PLE or PFE in case of a
general fluid) is a novel and eco-friendly approach for
the recovery of bioactives from plants. This method
often requires water as the solvent and so it can keep
away from the environmental and health risks due to the
use of organic solvents. Operating at high temperature
(till 200°C) and pressure (from 35 to 200 bar), PLE im-
proves the quality of the extraction that can be carried
out in a dynamic mode in which the solvent is inces-
santly pumped through the vessel, or in a static mode in
which there are more cycles with a continuous replace-
ment of the solvent [20]. At elevated temperatures there is
a reduction of the viscosity of the solvent that can better
penetrate the matrix extracting the analytes of interest,
even if this approach cannot be used for the thermally un-
stable compounds and it could lead to a co-extraction of
other compounds because of the decreased selectivity of
extraction at higher temperatures. The elevated pressure
permits maintaining the solvent in the liquid phase and
the disruption of plant cells wall exerting pressure on the
matrix. In place of organic solvents, it is possible to use
additives like non-ionic surfactants, antioxidants like as-
corbic acid, CO2 to drop aqueous pH or drying agents.
Furthermore, PLE apparatus protects light sensitive and
oxygen sensitive products from degradation, and it could
be hyphenated with other modern extractive techniques
like UAE to improve its efficacy.
Serenoa repens extracts: therapeutic properties and
implication for the treatment of BPH
Natural products recovered from plants and herbs have
been using for centuries for the treatment of several
pathologies including benign prostatic hyperplasia. Among
the phytotherapeutics used for BHP, bioactives extracted
from the fruit of the American dwarf palm S. repens is the
most widespread thanks to its safety, tolerability profile,
and clinical benefits. The composition of free fatty acids,
methyl and ethyl esters, long chain esters and glycerides
found in S. repens extracts (SrE) is different from a brand
to another according to the extractive strategy used [21].Although the specific mechanism of action of SrE has
not been completely understood yet, it has been reported
that the therapeutic agents could exert an inhibitory activ-
ity towards 5α-reductase, in addition to pro-apoptotic,
anti-estrogenic and anti-inflammatory properties [22].
In the past, two reviews compared a large number of
different brands of marketed S. repens extracts on the
basis of the quali-quantitative composition in free fatty
acids and their esterified forms [23] and on their corre-
sponding inhibitory activity against the two isoforms of
5α-reductase [24,25]. Results were contrasting among
these natural products (and above all among the batches
of the same product) and, consequently, their clinical
efficacy could be recognized different as well.
The database (Pubmed, Scifinder) investigation has been
directed towards the most recent and relevant studies re-
garding the biological properties and therapeutic applica-
tions of S. repens extracts and the comparison among
these commercial products. We chose “Serenoa repens”
and “Serenoa repens extraction” terms for the biblio-
graphic research. As a matter of this, we collected in
Table 2 studies on different extracts and active princi-
ples of S. repens to demonstrate how, despite the
pharmacological interest in this plant for the treatment
of lower urinary tract symptoms, little is known about
its phytochemical/pharmacological complexity and a better
standardization could improve the interchangeability
among these brand products.
From this synoptic summary it is possible to extrapolate
that:
 As regards Sabalselect® by Indena (supercritical
carbon dioxide extract, SFE), despite the high
content in free fatty acids, the quantitative
composition in its single components depends on
the natural source variability. The major findings of
this study are that lauric acid, oleic acid, myristic
acid and linoleic acid, the major constituents of SFE,
as well as SFE itself, actively bound to
pharmacologically relevant (α1-adrenergic,
muscarinic and 1,4-DHP) receptors in rat brain, and
significantly inhibited 5α-reductase activity in rat
liver. In addition, these components and the whole
extract were shown to inhibit specific binding of
[3H]prazosin in rat brain. Based on their IC50 values,
the affinity for α1-adrenergic, 1,4-DHP, and
muscarinic receptors displayed by linoleic acid, oleic
acid, and myristic acid was 1.3-4.5 times greater
than that of SFE. Conversely, the receptor binding
activity of lauric acid and palmitic acid was similar
to that of SFE. In general, the receptor binding
activity of unsaturated fatty acids tended to be
greater than that of saturated fatty acids (correlation
of the pharmacological activity with the degree of
Table 2 Different extracts of different brands of Serenoa repens discussed and compared in this review
Extract (composition) Extractiontechnique Isolated active compound (%) Ref.
Sabal Select (>90% free fatty acids or their esterified






Sabal Select (>90% free fatty acids or their esterified



















Esterified FAs represent 7%, while the rest is composed of








(86% total content of free fatty acids)











Talso, Talso uno Supercritical CO2
acid lipophilic compounds, fatty alcohols and sterols as main
components
[38]
Prostamol Uno Not reported Saturated and unsaturated fatty acids and phytosteroids [39,40]
ProstateEZE Max Not reported
Serenoa repens standardized to fatty acids, Pygeum africanum
standardized to β-sitosterol, Epilobium parviflorum, Cucurbita
pepo seed oil, lycopene
[41]
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acid, myristic acid and linoleic acid inhibited
5α-reductase activity in a concentration-dependent
manner. The inhibitory effect of each fatty acid was
similar or slightly more potent than that of SPE.
Consistent with these results, Raynaud et al.
reported that palmitic acid was inactive in the
inhibition of 5α-reductase [25]. The inhibitory effect
on 5α-reductase activity by each fatty acid was
roughly similar to their affinity for pharmacologically
relevant receptors [26,27]. In a recent research, the
effect on rat prostate gland contractility of this
extract was evaluated after fractioning. The
inhibition of prostatic smooth muscle contractionswas preferentially induced by the ethyl acetate fraction
(enriched in fatty acids) via a non-specific mechanism
(not involving the inhibition of protein kinase C,
myosin light chain kinase and Rho kinase) [28].
 Permixon® is the most studied extract in the
literature both regarding its anti-proliferative activity
and its anti-inflammatory ability. The former activity
has been demonstrated, for the hexanic extract,
against a large number of prostate carcinoma cell
lines (PC3 and LNCaP) where it caused growth
arrest and apoptosis at 50–80 μg/mL for 24–48 h
(but not in MCF7 breast cancer cells). Treatment of
cells with 100 μg/mL for 4 h resulted in morphological
changes with massive vacuolization and swelling
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changes in membrane composition and function).
Apoptosis seemed to depend on the intrinsic pathway,
which appears to be triggered by opening of the
mitochondrial PTP, a high-conductance channel
that is involved in many forms of cell death, and
complete release of mitochondrial TMRM (early
mitochondrial depolarization and loss of membrane
potential). Cell-cycle analysis showed the presence
of a sub-G1 peak, a decreased G0/G1 peak and an
accumulation of cells in G2/M phase after 48 h of
treatment [29,30].
With respect to the latter mechanism of action,
different research groups highlighted the
anti-inflammatory property of this plant. Multiple
inflammation functional systems, such as Cytokines
family, Glucocorticoid/PPAR signalling, MAPK
signalling, TNF superfamily, and COX/LOX
pathways, seemed to be modulated by LSESr
treatment. Recently, Latil et al. [31] have studied
how this biological property could be ascribed only
to the hexanic extract of this plant and not to the
supercritical CO2 extract. Both of the tested extracts
belonged to six different batches of the same plant
at Pierre Fabre Plantes et Industrie. Results showed
that the hexanic extract was responsible of a strong
attenuation of a large number of inflammation
mediators and markers. Moreover, inhibition of
MCP-1/CCL2 mRNA expression in a concentration-
dependent manner has been registered only for the
hexanic extract, whereas the supercritical CO2 ex-
tract was not endowed with this inhibitory effect.
This is the only one example in the literature of a
direct comparison of the different pharmacological
profile associated to two extraction techniques
showing the impact of this procedures on the quality/
efficacy of phytotherapeutic products [31-33];
 Prostasan® has been also studied both for its anti-
proliferative and anti-inflammatory activities (as an
ethanolic extract). Comparison of the obtained
results with respect to Permixon® led to similar
results in terms of low cytotoxicity against normal
cells, dose-dependent reduction of cellular growth
(especially in AR-positive prostate and ER-positive
breast cancer cells), apoptosis induction, inhibition
of IL-12, MCP-1 and GM-CSF secretion and,
consequently, decreased inflammatory processes and
production of cytokine pro-inflammatory from
macrophages. The content in free fatty acids is
almost comparable to that of Permixon®. Moreover,
inhibitory effects on the epithermal growth factor
(EGF) and the Gram-negative bacteria cell wall
component LPS-induced proliferation of prostatic
cells PC-3 were observed with this extract. In thecase of EGF, the mechanism involves competition
for the EGF receptor. LPS exerts a milder but still
significant induction on proliferation of prostate cells,
supporting the role of bacterial infection in the origin
of BPH. The mechanism behind S. repens extract
effecting LPS actions on prostatic cells remains to be
elucidated since it does not apparently affect Toll-like
receptor 4 intracellular signalling [34,35];
 Saw Palmetto Berry Powder (SPBE) biological
activity has been investigated with respect to its
phytosterols content. With increasing concentration,
the authors observed a reduction in cell growth
compared to control cells in the following order of
substance effectiveness: SPBE > β-sitosterol >
stigmasterol, and an increase in cell growth with
rising cholesterol concentration on prostate cancer
cells (DU145). Analysis of cell cycle regulating
proteins (p53, p27, p21) and 2D traction microscopy
were also performed. p53 increased after treatment
with this extract, whereas p27 and p21 decreased.
This report justifies the administration of the entire
phytocomplex to ensure a proper pharmacological
efficacy not limiting the interest only to free fatty
acids [36];
 PC-SPES is a combination of herbs containing
flavonoids, alkaloids, polysaccharides, amino acids,
and trace minerals. The 8 herbs used were
chrysanthemum, isatis, licorice, Ganoderma
lucidum, Panax pseudo-ginseng, Rabdosia rubescens,
saw palmetto, and skullcap. PC-SPES mediated an
anti-proliferative effect on prostate cancer cells
(LNCaP, DU145, and PC3) in vivo and in vitro,
induced apoptosis of LNCaP cells in a dose- and
time-dependent manner and reduced prostate
specific antigen (PSA) or AR levels in LNCaP cells
and in more than 80% of individuals with prostate
cancer. In addition in the same cell line, saw
palmetto might inhibit cell growth down-regulating
basal and DHT- or IL-6-induced PSA expression in
cytoplasmic protein and AR expression in nuclear
proteins. Previous studies have demonstrated that
STAT3 signalling has a critical role in the tumour
formation of prostate cancer and IL-6 treatment
results in the activation of STAT3 in prostate cancer
cells. This extract down-regulated the IL-6-induced
level of the phosphorylated form of STAT3 in
LNCaP cells blocking this pathway and markedly
inhibiting the growth of LNCaP cells [37];
 The SG 291 extract (Talso, Talso uno) was analyzed
by gas chromatography and investigated for its dual
inhibitory influence on cyclooxygenase (COX,
IC50 = 28.1 μg/mL) and 5-lipoxygenase (5-LOX,
IC50 = 18 μg/mL). After alkaline hydrolysis, ether
extraction and preparative TLC the SG 291 extract
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lipophilic compounds (A), fatty alcohols (B) and
sterols (C). Only fraction A inhibited COX and
5-LOX as the native SG 291 extract, whereas the
fractions B, C and β-sitosterol showed no inhibitory
effect on both enzymes [38].
 Prostamol Uno (Berlin-Chemie AG/Menarini
Group) was shown to possess anti-inflammatory and
antiedematous effects reducing the proliferation of
prostatic epithelium. Moreover, its pharmacological
activity in rats with BPH was compared to that of a
complex of peptides isolated from the cattle prostate.
The results showed that both treatments reduced the
acinar epithelial area in this experimental model, but
the response to S. repens extract was characterized by
an enhanced stromal/epithelial proportion [39]. In
addition, the safety and tolerability of this extract have
been evaluated in two dosage regimes in experimental
animals [40].
 ProstateEZE Max (Caruso’s Natural Health) is an
orally dosed herbal preparation containing S. repens
(660 mg/day), among other prostatotropic agents of
natural origin (Cucurbita pepo, Epilobium
parviflorum, lycopene and Pygeum africanum). It
has been studied in a short-term phase II randomized
double-blind placebo controlled clinical trial to
evaluate its efficacy and safety [41]. This combination
of herbal extracts behaved as an effective treatment in
the management of symptoms of BPH.
 Profluss® by Konpharma: to evaluate its efficacy on
prostatic chronic inflammation, 168 subjects affected
by LUTS due to bladder outlet obstruction were
enrolled and subjected to Profluss with or without
α-blockers treatment (“Flogosis And Profluss in
Prostatic and Genital Disease” (FLOG) study). At
follow-up there were statistical significant
reductions of extension and grading of flogosis
(mean values of CD20, CD3, CD68, and PSA). This
product may have an anti-inflammatory activity
that could be of interest in the treatment of PCI in
BPH [42].
 SeR alcoholic extract, provided by Bernett, has been
recently studied (alone and in association with
selenium and lycopene) for the impact on the bax/
bcl-2 ratio, caspase-3 activity, IAPs and survivin
expression, and cytokines production in prostatic
specimens from BPH patients. These analyses
suggested that the impairment in the extrinsic
pathway does not contribute to the cell death
program in BPH, that the administration of SeR,
either alone or in association, markedly mitigated
survivin expression. Moreover, the expression of
IL-6 was reduced preventing the histological features
of BPH and inhibiting growth by 43.3% [43].Review and conclusions
Benign prostate hyperplasia is one of the most common
diseases in male population. In addition to pharmaco-
logical therapy with α-blockers or 5α-reductase inhibi-
tors, also bioactive compounds derived from plants play
an important role in the treatment of BPH associated to
LUTS. Despite the benefits obtained from SrE, the var-
iety of the extractive techniques and strategies makes
one extract different from another in terms of bioactives
composition and this could affect the quality and the
clinical effects of natural therapies of different brands
even if derived from the same plant. Thus, the clinical
and biological activities of one preparation cannot be
extrapolated to other preparations of the same plant
source. Moreover, standardization of the composition
through alternative and more reproducible techniques
is warranted due to the complex pharmacological pro-
file of the whole phytocomplex of S. repens. Results
from different clinical trials must be compared strictly
according to the same validated extraction technique
and/or content in active principles.
At this time, few studies made a comparison among
these different extracts. The solvent (hexane) extraction
of lipidosterolic composition from S. repens is the most
investigated in clinical and experimental trials although
further large comparative trials should explore the possible
clinical influence of the different extractions processes.
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